Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198706 | 0.82 | MMP1 (0.39) | RECQLALOX12LMNA | |
| SCHEMBL12191340 | 0.82 | MMP1 (0.39) | RECQLALOX12LMNA | |
| SCHEMBL7550278 | 0.82 | MMP1 (0.39) | RECQLALOX12LMNA | |
| SCHEMBL7557080 | 0.79 | ALDH1A1 (0.35) | USP2ALDH1A1HPGDL3MBTL1LMNA | |
| SCHEMBL7541895 | 0.76 | ATM (0.40) | ALDH1A1SMN1; SMN2HPGDGAA | |
| SCHEMBL15038847 | 0.71 | RECQL (1.00) | RECQLUSP2ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL20663584 | 0.71 | RECQL (1.00) | RECQLUSP2ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL13081566 | 0.70 | ALDH1A1 (0.40) | RECQLALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL7605162 | 0.70 | ALDH1A1 (0.40) | RECQLALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL7602707 | 0.70 | HTT (0.45) | ALDH1A1SMN1; SMN2HPGDGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | RECQL 648/4885USP2 1767/4885ALOX15 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.